Ann: December 2020 Quarterly Activities Report and Appendix 4C, page-7

Thanks @patyccc that makes sense.

@aruc6393 Agree, it is dragging on but COVID wasn't exactly in their roadmap. Fact is there is not much that can be done until pathology labs can get a break from COVID testing. I would strongly urge anyone to sell now if they aren't prepared to wait this out.

Yes cash burn was high but for good reason, as mentioned in the quarterly:




That's allot of consultancy work (usually billed in hours).

As a FYI to anyone interested, the Payer Budget study was done by our friends over at Renalytix about a year ago.
https://renalytixai.com/wp-content/uploads/2020/03/BHA-Renalytix-KidneyIntelX-NKF-Poster-3.25.20-FINAL-002.pdf
They received their CPT code 3 months after publication.

I am confident Richard and the team will secure the reimbursement code this calendar year. This will be very significant milestone and significantly de-risk our investment here.